{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T13:33:30Z","timestamp":1789911210477,"version":"4.0.1"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2016,2,1]],"date-time":"2016-02-01T00:00:00Z","timestamp":1454284800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100004628","name":"MedImmune","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004628","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2016,2]]},"DOI":"10.1007\/s12325-016-0287-8","type":"journal-article","created":{"date-parts":[[2016,2,3]],"date-time":"2016-02-03T07:59:39Z","timestamp":1454486379000},"page":"225-251","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":40,"title":["Pharmacokinetics, Pharmacodynamics, and Safety of MEDI4212, an Anti-IgE Monoclonal Antibody, in Subjects with Atopy: A Phase I Study"],"prefix":"10.1007","volume":"33","author":[{"given":"Eric","family":"Sheldon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Schwickart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keunpyo","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Crouch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaista","family":"Parveen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris","family":"Kell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Birrell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,2,3]]},"reference":[{"key":"287_CR1","doi-asserted-by":"crossref","first-page":"354250","DOI":"10.1155\/2014\/354250","volume":"2014","author":"SF Thomsen","year":"2014","unstructured":"Thomsen SF. Atopic dermatitis: natural history, diagnosis, and treatment. ISRN Allergy. 2014;2014:354250.","journal-title":"ISRN Allergy"},{"key":"287_CR2","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1186\/2047-783X-16-9-407","volume":"16","author":"P Velling","year":"2011","unstructured":"Velling P, Skowasch D, Pabst S, Jansen E, Tuleta I, Grohe C. Improvement of quality of life in patients with concomitant allergic asthma and atopic dermatitis: one year follow-up of omalizumab therapy. Eur J Med Res. 2011;16:407\u201310.","journal-title":"Eur J Med Res"},{"key":"287_CR3","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/s40521-013-0006-5","volume":"1","author":"K Marth","year":"2014","unstructured":"Marth K, Focke-Tejkl M, Lupinek C, Valenta R, Niederberger V. Allergen peptides, recombinant allergens and hypoallergens for allergen-specific immunotherapy. Curr Treat Options Allergy. 2014;1:91\u2013106.","journal-title":"Curr Treat Options Allergy"},{"key":"287_CR4","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/S1081-1206(10)60928-3","volume":"97","author":"I Baiardini","year":"2006","unstructured":"Baiardini I, Braido F, Brandi S, Canonica GW. Allergic diseases and their impact on quality of life. Ann Allergy Asthma Immunol. 2006;97:419\u201328.","journal-title":"Ann Allergy Asthma Immunol"},{"key":"287_CR5","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1146\/annurev.immunol.21.120601.141103","volume":"21","author":"HJ Gould","year":"2003","unstructured":"Gould HJ, Sutton BJ, Beavil AJ, et al. The biology of IgE and the basis of allergic disease. Annu Rev Immunol. 2003;21:579\u2013628.","journal-title":"Annu Rev Immunol"},{"key":"287_CR6","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/S0065-2776(06)93002-8","volume":"93","author":"TW Chang","year":"2007","unstructured":"Chang TW, Wu PC, Hsu CL, Hung AF. Anti-IgE antibodies for the treatment of IgE-mediated allergic diseases. Adv Immunol. 2007;93:63\u2013119.","journal-title":"Adv Immunol"},{"key":"287_CR7","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1038\/nri3632","volume":"14","author":"LC Wu","year":"2014","unstructured":"Wu LC, Zarrin AA. The production and regulation of IgE by the immune system. Nat Rev Immunol. 2014;14:247\u201359.","journal-title":"Nat Rev Immunol"},{"key":"287_CR8","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1038\/367183a0","volume":"367","author":"AS Gounni","year":"1994","unstructured":"Gounni AS, Lamkhioued B, Ochiai K, et al. High-affinity IgE receptor on eosinophils is involved in defence against parasites. Nature. 1994;367:183\u20136.","journal-title":"Nature"},{"key":"287_CR9","doi-asserted-by":"crossref","first-page":"S73","DOI":"10.1016\/j.jaci.2009.11.017","volume":"125","author":"KD Stone","year":"2010","unstructured":"Stone KD, Prussin C, Metcalfe DD. IgE, mast cells, basophils, and eosinophils. J Allergy Clin Immunol. 2010;125:S73\u201380.","journal-title":"J Allergy Clin Immunol"},{"key":"287_CR10","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.jaci.2004.05.038","volume":"114","author":"N Novak","year":"2004","unstructured":"Novak N, Allam JP, Hagemann T, et al. Characterization of FcepsilonRI-bearing CD123 blood dendritic cell antigen-2 plasmacytoid dendritic cells in atopic dermatitis. J Allergy Clin Immunol. 2004;114:364\u201370.","journal-title":"J Allergy Clin Immunol"},{"key":"287_CR11","doi-asserted-by":"crossref","first-page":"5724","DOI":"10.4049\/jimmunol.175.9.5724","volume":"175","author":"JT Schroeder","year":"2005","unstructured":"Schroeder JT, Bieneman AP, Xiao H, et al. TLR9- and FceRI-mediated responses expression dendritic cells by down-regulating receptor oppose one another in plasmacytoid. J Immunol. 2005;175:5724\u201331.","journal-title":"J Immunol"},{"key":"287_CR12","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.4049\/jimmunol.158.3.1438","volume":"158","author":"DW MacGlashan Jr","year":"1997","unstructured":"MacGlashan DW Jr, Bochner BS, Adelman DC, et al. Down-regulation of Fc(epsilon)RI expression on human basophils during in vivo treatment of atopic patients with anti-IgE antibody. J Immunol. 1997;158:1438\u201345.","journal-title":"J Immunol"},{"key":"287_CR13","doi-asserted-by":"crossref","first-page":"5624","DOI":"10.4049\/jimmunol.162.9.5624","volume":"162","author":"SS Saini","year":"1999","unstructured":"Saini SS, MacGlashan DW Jr, Sterbinsky SA, et al. Down-regulation of human basophil IgE and FC epsilon RI alpha surface densities and mediator release by anti-IgE-infusions is reversible in vitro and in vivo. J Immunol. 1999;162:5624\u201330.","journal-title":"J Immunol"},{"key":"287_CR14","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/j.jaci.2004.06.032","volume":"114","author":"LA Beck","year":"2004","unstructured":"Beck LA, Marcotte GV, MacGlashan D, Togias A, Saini S. Omalizumab-induced reductions in mast cell Fce psilon RI expression and function. J Allergy Clin Immunol. 2004;114:527\u201330.","journal-title":"J Allergy Clin Immunol"},{"key":"287_CR15","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1016\/j.jaci.2003.10.003","volume":"112","author":"C Prussin","year":"2003","unstructured":"Prussin C, Griffith DT, Boesel KM, Lin H, Foster B, Casale TB. Omalizumab treatment downregulates dendritic cell FcepsilonRI expression. J Allergy Clin Immunol. 2003;112:1147\u201354.","journal-title":"J Allergy Clin Immunol"},{"key":"287_CR16","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1016\/j.rmed.2009.03.008","volume":"103","author":"S Holgate","year":"2009","unstructured":"Holgate S, Buhl R, Bousquet J, Smith N, Panahloo Z, Jimenez P. The use of omalizumab in the treatment of severe allergic asthma: a clinical experience update. Respir Med. 2009;103:1098\u2013113.","journal-title":"Respir Med"},{"key":"287_CR17","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/j.jaip.2014.03.010","volume":"2","author":"M Humbert","year":"2014","unstructured":"Humbert M, Busse W, Hanania NA, Lowe PJ, Canvin J, Erpenbeck VJ, Holgate S. Omalizumab in asthma: an update on recent developments. J Allergy Clin Immunol Pract. 2014;2:525\u201336.","journal-title":"J Allergy Clin Immunol Pract"},{"key":"287_CR18","unstructured":"Novartis. Omalizumab EU product information. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/000606\/WC500057298.pdf . Accessed 5 Dec 2014."},{"key":"287_CR19","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1056\/NEJMoa1215372","volume":"368","author":"M Maurer","year":"2013","unstructured":"Maurer M, Rosen K, Hsieh HJ, et al. Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria. N Engl J Med. 2013;368:924\u201335.","journal-title":"N Engl J Med"},{"key":"287_CR20","doi-asserted-by":"crossref","first-page":"724","DOI":"10.4161\/mabs.22216","volume":"4","author":"DL Mortensen","year":"2012","unstructured":"Mortensen DL, Prabhu S, Stefanich EG, et al. Effect of antigen binding affinity and effector function on the pharmacokinetics and pharmacodynamics of anti-IgE monoclonal antibodies. MAbs. 2012;4:724\u201331.","journal-title":"MAbs"},{"key":"287_CR21","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1208\/s12248-008-9045-4","volume":"10","author":"WS Putnam","year":"2008","unstructured":"Putnam WS, Li J, Haggstrom J, et al. Use of quantitative pharmacology in the development of HAE1, a high-affinity anti-IgE monoclonal antibody. AAPS J. 2008;10:425\u201330.","journal-title":"AAPS J"},{"key":"287_CR22","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1111\/cea.12400","volume":"44","author":"JP Arm","year":"2014","unstructured":"Arm JP, Bottoli I, Skerjanec A, et al. Pharmacokinetics, pharmacodynamics and safety of QGE031 (ligelizumab), a novel high-affinity anti-IgE antibody, in atopic subjects. Clin Exp Allergy. 2014;44:1371\u201385.","journal-title":"Clin Exp Allergy"},{"key":"287_CR23","doi-asserted-by":"crossref","first-page":"756","DOI":"10.4161\/mabs.28394","volume":"6","author":"ES Cohen","year":"2014","unstructured":"Cohen ES, Dobson CL, Kack H, et al. A novel IgE-neutralizing antibody for the treatment of severe uncontrolled asthma. MAbs. 2014;6:756\u201364.","journal-title":"MAbs"},{"key":"287_CR24","unstructured":"GINA Report. Global strategy for asthma management and prevention. 2007. http:\/\/www.ginasthma.org ."},{"key":"287_CR25","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1111\/j.1742-7843.2005.pto960307.x","volume":"96","author":"GM Meno-Tetang","year":"2005","unstructured":"Meno-Tetang GM, Lowe PJ. On the prediction of the human response: a recycled mechanistic pharmacokinetic\/pharmacodynamic approach. Basic Clin Pharmacol Toxicol. 2005;96:182\u201392.","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"287_CR26","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1111\/j.1365-2125.2006.02803.x","volume":"63","author":"N Hayashi","year":"2007","unstructured":"Hayashi N, Tsukamoto Y, Sallas WM, Lowe PJ. A mechanism-based binding model for the population pharmacokinetics and pharmacodynamics of omalizumab. Br J Clin Pharmacol. 2007;63:548\u201361.","journal-title":"Br J Clin Pharmacol"},{"key":"287_CR27","doi-asserted-by":"crossref","first-page":"756","DOI":"10.4161\/mabs.28394","volume":"6","author":"ES Cohen","year":"2014","unstructured":"Cohen ES, Dobson CL, Kack H, et al. A novel IgE-neutralizing antibody for the treatment of severe uncontrolled asthma. MAbs. 2014;6:756\u201364.","journal-title":"MAbs"},{"key":"287_CR28","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1111\/j.1365-2125.2009.03401.x","volume":"68","author":"PJ Lowe","year":"2009","unstructured":"Lowe PJ, Tannenbaum S, Gautier A, Jimenez P. Relationship between omalizumab pharmacokinetics, IgE pharmacodynamics and symptoms in patients with severe persistent allergic (IgE-mediated) asthma. Br J Clin Pharmacol. 2009;68:61\u201376.","journal-title":"Br J Clin Pharmacol"},{"key":"287_CR29","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1111\/j.1365-2125.2011.03962.x","volume":"72","author":"PJ Lowe","year":"2011","unstructured":"Lowe PJ, Renard D. Omalizumab decreases IgE production in patients with allergic (IgE-mediated) asthma; PKPD analysis of a biomarker, total IgE. Br J Clin Pharmacol. 2011;72:306\u201320.","journal-title":"Br J Clin Pharmacol"},{"key":"287_CR30","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1172\/JCI109103","volume":"62","author":"FJ Malveaux","year":"1978","unstructured":"Malveaux FJ, Conroy MC, Adkinson NF Jr, Lichtenstein LM. IgE receptors on human basophils. Relationship to serum IgE concentration. J Clin Invest. 1978;62:176\u201381.","journal-title":"J Clin Invest"},{"key":"287_CR31","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.4049\/jimmunol.167.3.1290","volume":"167","author":"TA Borkowski","year":"2001","unstructured":"Borkowski TA, Jouvin MH, Lin SY, Kinet JP. Minimal requirements for IgE-mediated regulation of surface Fc epsilon RI. J Immunol. 2001;167:1290\u20136.","journal-title":"J Immunol"},{"key":"287_CR32","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1189\/jlb.70.2.207","volume":"70","author":"D MacGlashan Jr","year":"2001","unstructured":"MacGlashan D Jr, Xia HZ, Schwartz LB, Gong J. IgE-regulated loss, not IgE-regulated synthesis, controls expression of FcepsilonRI in human basophils. J Leukoc Biol. 2001;70:207\u201318.","journal-title":"J Leukoc Biol"},{"key":"287_CR33","doi-asserted-by":"crossref","first-page":"183","DOI":"10.2165\/00151829-200403030-00006","volume":"3","author":"LM Bang","year":"2004","unstructured":"Bang LM, Plosker GL. Omalizumab: a review of its use in the management of allergic asthma. Treat Respir Med. 2004;3:183\u201399.","journal-title":"Treat Respir Med"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-016-0287-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12325-016-0287-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-016-0287-8","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,16]],"date-time":"2023-08-16T18:43:45Z","timestamp":1692211425000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12325-016-0287-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,2]]},"references-count":33,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2016,2]]}},"alternative-id":["287"],"URL":"https:\/\/doi.org\/10.1007\/s12325-016-0287-8","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,2]]}}}